You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新一批約95.6萬劑復必泰疫苗付運抵港
阿思達克 08-06 15:35
政府公布,復星醫藥(02196.HK)將BioNTech製造並於德國Baxter廠房封裝的最新一批約95.6萬劑復必泰疫苗付運抵港。 新一批次復必泰疫苗今日抵港後,工作人員隨即按既定程序,對有關疫苗進行檢查及核對,以確保疫苗符合產品規格及相關的冷鏈運輸標準。政府亦會把疫苗存放在經驗證的超低溫冷藏櫃,按藥廠指定的溫度妥善保存。這批疫苗的藥瓶標籤包含英文及簡體中文,是根據已批准的規格在德國的藥廠製造及封裝。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account